In an SEC filing on Wednesday CVS said that it is “determined that its LTC business was no longer a strategic asset, and during the third quarter of 2022 committed to a plan to sell.”
Walgreens and CVS Health separately announced agreements intended to resolve opioid-related litigation, while outlining initiatives taken to respond to the opioid crisis.